Support-t Online Training in Youth Living With Type 1 Diabetes Transitioning to Adult Care

Sponsor
McGill University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05910840
Collaborator
McGill University Health Centre/Research Institute of the McGill University Health Centre (Other), Centre de recherche du Centre hospitalier universitaire de Sherbrooke (Other), CSSS de Gatineau (Other), CHU de Quebec-Universite Laval (Other)
200
4
2
43
50
1.2

Study Details

Study Description

Brief Summary

The investigators will conduct a randomized controlled trial (RCT) to examine how an online training and peer support platform could help the preparation to transition to adult care. Among 14-16 year old youth with Type 1 Diabetes (T1D), the investigators aim to assess the effect of an online training and peer support platform (Support-t) integrated in usual care, compared with usual care on Hemoglobin A1c (HbA1c), adverse outcomes and psychosocial measures during the preparation for transition to adult care. The investigators will conduct a multi-site, parallel group, blinded (outcome assessors, data analysts), superiority RCT of adolescents with T1D (14-16 years of age) followed at one of 4 university teaching hospital-based pediatric diabetes clinics in the province of Quebec.

Detailed Description

The transition from pediatric to adult diabetes care is a challenging period for adolescents and young adults living with chronic conditions, such as Type 1 Diabetes (T1D). For youth with T1D, transition from pediatric to adult care is characterized by deterioration in glycemic control (Hemoglobin A1c [HbA1c]), reduced adherence to diabetes management tasks and increased risk of diabetes complications. The investigators propose to examine an online training and peer support platform as a potential alternative for delivering transition care. In adolescents with T1D, the investigators hypothesize that an online training and peer support platform (Support-t), when integrated into usual pediatric care, as compared with usual care alone, will result in better HbA1c, less adverse outcomes and better psychosocial outcomes during the preparation for transfer to adult care.

Primary Aim: To determine the impact of adding access to Support-t to usual care compared with usual care alone, on HbA1c during the preparation for transfer to adult care.

Secondary Aims: To determine the impact of adding access to Support-t to usual care compared with usual care alone, on self-efficacy, diabetes distress, quality of life (QOL; diabetes specific), readiness to transfer to adult care, glucose management, severe hypoglycemic episodes, diabetic ketoacidosis (DKA), T1D-related ED-visits and hospitalizations during the preparation for transfer to adult care. 2. To determine the cost-effectiveness of Support-t. 3. To understand the context for implementation in regards to level of engagement on Support-t, satisfaction and experience (barriers, facilitators) with Support-t.

Methods: The investigators will conduct a multi-site, parallel group, blinded (outcome assessors, data analysts), superiority RCT of adolescents with T1D (14-16 years of age) followed at one of 4 university teaching hospital-based pediatric diabetes clinics in Quebec. Patients will be recruited over 20 months. Interventions will occur over 18 months. Follow-up will be to 18 months from enrollment. Allocation will be concealed with a 1:1 intervention to control ratio. Participants in the active arm will have access to a mobile-based online training and peer support platform (Support-t) added to usual care. Participants in the control group will have in parallel with the intervention group, their usual diabetes care. The primary outcome is the change in HbA1c measured at 18 months (HbA1c measured at 18 months

  • HbA1c measured at baseline). Secondary outcomes are self-efficacy, diabetes distress, QOL, readiness to transfer, glucose management, severe hypoglycemic episodes, DKA, T1D-related ED-visits and hospitalizations. Assessments are at baseline, 6, 12 and 18 months. Analysis will be by intention-to-treat. Outcomes will be calculated and compared between the 2 trial arms using differences with 95% Confidence Intervals, along with a cost-effectiveness analysis. Interviews will be conducted to analyze the context for implementation.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
200 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Active arm: Participants randomized to the active arm will have access to the Support-t online training and peer support platform in addition to their usual diabetes care, over the 18 month intervention period. Support-t contains 3 components: 1) Educational material, 2) News blog and 3) Patients' discussion forum. Control arm: Participants randomized to usual care only will attend their usual diabetes clinic visits, over the 18-month intervention period, which consists of visits with their health care provider and ad-hoc diabetes education with nurses and dietitians.Active arm: Participants randomized to the active arm will have access to the Support-t online training and peer support platform in addition to their usual diabetes care, over the 18 month intervention period. Support-t contains 3 components: 1) Educational material, 2) News blog and 3) Patients' discussion forum. Control arm: Participants randomized to usual care only will attend their usual diabetes clinic visits, over the 18-month intervention period, which consists of visits with their health care provider and ad-hoc diabetes education with nurses and dietitians.
Masking:
Single (Outcomes Assessor)
Masking Description:
Data analysts
Primary Purpose:
Supportive Care
Official Title:
Support-t, an Online Training and Peer Support Platform to Accompany Youth Living With Type 1 Diabetes Transitioning to Adult Healthcare
Anticipated Study Start Date :
Nov 1, 2023
Anticipated Primary Completion Date :
Dec 31, 2026
Anticipated Study Completion Date :
Jun 1, 2027

Arms and Interventions

Arm Intervention/Treatment
Experimental: Support-t plus usual diabetes care

Access to the Support-t online training and peer support platform in addition to usual diabetes care for 18 months. Support-t contains 3 components: 1) Educational material, 2) News blog and 3) Patients' discussion forum. Health care providers from the pediatric diabetes clinics will receive Support-t training and will be encouraged to recommend the Support-t platform during routine care with their patients from the active arm.

Other: Support-t
Support-t plus usual diabetes care for 18 months

No Intervention: Usual diabetes care only

Usual diabetes care for 18 months, which consists of visits with their health care provider and ad-hoc diabetes education with nurses and dietitians. Health care providers from the pediatric diabetes clinics will be instructed not to discuss or refer to the Support-t platform with patients from the control arm. Control arm participants will have the option to use the Support-t platform after the 18-month study.

Outcome Measures

Primary Outcome Measures

  1. Change from Baseline Hemaglobin A1c (HbA1c) at 18 months [18 months]

    HbA1c measured with a venous or capillary blood sample as part of the standard of diabetes care will be derived from the medical record chart or measured using an A1c Test Kit, which is a non-fasting, finger prick, whole blood test

Secondary Outcome Measures

  1. Change from Baseline Hemaglobin A1c (HbA1c) at 6 and 12 months [6, 12 months]

    HbA1c measured with a venous or capillary blood sample as part of the standard of diabetes care will be derived from the medical record chart or measured using an A1c Test Kit, which is a non-fasting, finger prick, whole blood test

  2. Continuous Glucose Monitoring (CGM) - % Time in range [0, 6, 12, 18 months]

    % Time in range (3.9-10.0mmol/L) over the past 4 weeks will be derived from the medical record chart

  3. Continuous Glucose Monitoring (CGM) - % Time above range [0, 6, 12, 18 months]

    % Time above range (3.9-10.0mmol/L) over the past 4 weeks will be derived from the medical record chart

  4. Continuous Glucose Monitoring (CGM) - % Time below range [0, 6, 12, 18 months]

    % Time below range (3.9-10.0mmol/L) over the past 4 weeks will be derived from the medical record chart

  5. Continuous Glucose Monitoring (CGM) - Standard deviation [0, 6, 12, 18 months]

    Standard deviation of the past 4 weeks will be derived from the medical record chart

  6. Continuous Glucose Monitoring (CGM) - % Coefficient of variation [0, 6, 12, 18 months]

    % Coefficient of variation of the past 4 weeks will be derived from the medical record chart

  7. Severe hypoglycemic events [0, 6, 12, 18 months]

    Any severe hypoglycemic events in the past 6 months will be derived from self-report and from the medical record chart

  8. Diabetic Ketoacidosis (DKA) events [0, 6, 12, 18 months]

    Any Diabetic Ketoacidosis (DKA) events in the past 6 months will be derived from self-report and from the medical record chart

  9. Diabetes-related hospitalizations [0, 6, 12, 18 months]

    Any diabetes-related hospitalizations in the past 6 months, expressed as number of hospitalizations per person-years (P-Y) at risk will be derived from self-report and from the medical record chart

  10. Diabetes-related emergency department visits [0, 6, 12, 18 months]

    Any diabetes-related emergency-department visits in the past 6 months, expressed as number of emergency department visits per person-years (P-Y) at risk will be derived from self-report and from the medical record chart

  11. Self-efficacy [0, 6, 12, 18 months]

    Self-efficacy for Diabetes Self-Management Measure (SEDM) assesses self-efficacy. The score ranges from 1 to 10. All item scores are averaged to compute the score. A higher score represents a better outcome.

  12. Diabetes distress [0, 6, 12, 18 months]

    Problem Areas in Diabetes Scale-Teen (PAID-T) assesses adolescent diabetes distress. The scores range from 14 to 84. A total distress score is computed by summing responses. Higher scores indicate youth perception of feeling more burdened related to T1D.

  13. Diabetes specific Quality of Life (QOL) [0, 6, 12, 18 months]

    Type 1 Diabetes and Life (T1DAL) questionnaire assesses diabetes specific QOL for 12-17 year old adolescents living with T1D. Scores are transformed on a scale from 0 to 100. The total score ranges from 0 to 100. To calculate the total score, the mean is computed as the sum of all item scores divided by the number of items answered on all the scales. A higher total score represents a better outcome. The subscale scores (Daily Emotional Experiences & Daily Activities, Handling Diabetes Well, Peer Relationships, and Family Relationships) range from 0 to 100. To calculate the subscale scores, the mean is computed as the sum of the items in the subscale divided by the number of items answered on the subscale. Higher subscale scores represent a better outcome.

  14. Transition readiness [0, 6, 12, 18 months]

    Readiness Assessment of Emerging Adults with Type 1 Diabetes Diagnosed in Youth (READDY) assesses diabetes-related knowledge or skill items by querying respondents on 42 total items split into 5 domains: knowledge, navigation, health behaviors, and insulin pump skills. Respondents answer on a Likert scale from "yes, I can do this" scored 5 to "Haven't thought about it" scored 1. Confidence level is evaluated in each domain with a higher score indicating more confidence.

  15. Cost effectiveness (HbA1c) [12 and 18 months]

    Cost effectiveness of access to Support-t in addition to usual care compared with usual care in terms of incremental cost effectiveness ratio (ICER) for HbA1c

  16. Cost effectiveness (self-efficacy) [12 and 18 months]

    Cost effectiveness of access to Support-t in addition to usual care compared with usual care in terms of incremental cost effectiveness ratio (ICER) for self-efficacy

  17. Cost effectiveness (diabetes distress) [12 and 18 months]

    Cost effectiveness of access to Support-t in addition to usual care compared with usual care in terms of incremental cost effectiveness ratio (ICER) for diabetes distress

  18. Cost effectiveness (QOL) [12 and 18 months]

    Cost effectiveness of access to Support-t in addition to usual care compared with usual care in terms of incremental cost effectiveness ratio (ICER) for QOL

Other Outcome Measures

  1. Engagement with Support-t platform - T1D patient [6, 12, 18 months]

    Engagement metrics will be extracted using Google analytics (e.g. time spent on the platform, participation in the discussion forum, specific content accessed, total pages viewed, downloaded documents, use of calculators).

  2. Engagement with Support-t platform - Health Care Provider [6, 12 months]

    Engagement metrics will be extracted using Google analytics (e.g. time spent on the platform, specific content accessed, total pages viewed, downloaded documents, use of calculators).

  3. Satisfaction with Support-t platform - T1D patient [6, 12, 18 months]

    Satisfaction will be rated on a scale from 1 to 10. Higher scores indicate greater satisfaction with the platform.

  4. Experience with Support-t platform (Barriers, facilitators, satisfaction, fidelity) - T1D patient [18 months]

    Individual interviews to understand the experience in the context of implementation of the Support-t platform (Barriers, facilitators, satisfaction, fidelity) using qualitative descriptive methodology

  5. Experience with Support-t platform (Barriers, facilitators, satisfaction, fidelity) - Health Care Provider [12 months]

    Individual interviews to understand the experience in the context of implementation of the Support-t platform (Barriers, facilitators, satisfaction, fidelity) using qualitative descriptive methodology

Eligibility Criteria

Criteria

Ages Eligible for Study:
14 Years to 16 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Adolescents with a clinical diagnosis of T1D

  • 14-16 years of age

  • Receiving diabetes care at one of 4 university teaching hospital-based pediatric diabetes clinics in Quebec: Montreal Children's Hospital-McGill University Health Centre, Centre hospitalier universitaire de Sherbrooke, Le Copain-Hôpital de Gatineau, Centre Hospitalier Universitaire de Québec

  • Having access to internet

  • Having an active email address

  • Fluent in English or French

Exclusion Criteria:
  • Severe neurocognitive disabilities

  • Patients with conditions associated with shortened erythrocyte survival, such as hemolytic anemia or other conditions associated with inaccurate HbA1c

Contacts and Locations

Locations

Site City State Country Postal Code
1 Clinique de pédiatrie Le Copain-Hôpital de Gatineau Gatineau Canada
2 Montreal Children's Hospital - McGill University Health Centre Montréal Canada
3 Centre Hospitalier Universitaire de Québec Québec Canada
4 Centre Hospitalier Universitaire de Sherbrooke Sherbrooke Canada

Sponsors and Collaborators

  • McGill University
  • McGill University Health Centre/Research Institute of the McGill University Health Centre
  • Centre de recherche du Centre hospitalier universitaire de Sherbrooke
  • CSSS de Gatineau
  • CHU de Quebec-Universite Laval

Investigators

  • Principal Investigator: Anne-Sophie Brazeau, PhD, School of Human Nutrition - McGill University

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
McGill University
ClinicalTrials.gov Identifier:
NCT05910840
Other Study ID Numbers:
  • MP-37-2024-9734
First Posted:
Jun 20, 2023
Last Update Posted:
Jun 20, 2023
Last Verified:
Jun 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by McGill University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 20, 2023